BridgeBio Pharma, Inc.

BBIO · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$543-$643-$485-$586
Dep. & Amort.$6$6$7$6
Deferred Tax$0$0$0-$31
Stock-Based Comp.$96$0$92$100
Change in WC$32$5$28-$4
Other Non-Cash-$111$104-$61$18
Operating Cash Flow-$521-$528-$419-$498
Investing Activities
PP&E Inv.-$1-$1-$5-$48
Net Acquisitions-$0$0$0-$35
Inv. Purchases-$88-$137-$193-$643
Inv. Sales/Matur.$158$193$533$477
Other Inv. Act.-$8-$1$119$49
Investing Cash Flow$61$54$453-$201
Financing Activities
Debt Repay.$477$0-$20$1,080
Stock Issued$315$450$5$0
Stock Repurch.-$8-$7-$2-$205
Dividends Paid$0$0$0$0
Other Fin. Act.-$35$9$4-$138
Financing Cash Flow$748$452-$13$736
Forex Effect$0$0$0$0
Net Chg. in Cash$289-$22$21$38
Supplemental Information
Beg. Cash$395$417$396$359
End Cash$683$395$417$396
Free Cash Flow-$522-$529-$426-$546